磁共振体素内不相干运动-弥散加权成像定量参数预测KRAS突变非小细胞肺癌患者一线同步放化疗预后的价值

Prognostic value of intra-voxel incoherent motion-diffusion weighted imaging quantitative parameters in predicting prognosis of patients with KRAS mutation non-small cell lung cancer undergoing first-line concurrent chemoradiotherapy

  • 摘要:
    目的 探讨磁共振体素内不相干运动-弥散加权成像(IVIM-DWI)定量参数预测Kirsten大鼠肉瘤病毒癌基因同源物(KRAS)突变非小细胞肺癌(NSCLC)患者一线同步放化疗预后的价值。
    方法 选取139例KRAS突变NSCLC患者作为研究对象,其均接受一线同步放化疗。根据随访结果(随访终点事件定义为患者1年内发生全因死亡)将患者分为预后良好组和预后不良组。比较2组的一般资料、IVIM-DWI定量参数表观扩散系数(ADC)、扩散系数(D)、假扩散系数(D*)和灌注分数(f)。采用COX回归方程分析KRAS突变NSCLC患者预后不良的影响因素。绘制受试者工作特征(ROC)曲线分析IVIM-DWI定量参数预测KRAS突变NSCLC患者预后的价值。采用Kaplan-Meier(K-M)生存曲线和Log-rank检验分析IVIM-DWI定量参数与KRAS突变NSCLC患者预后的关系。
    结果 139例患者中共有4例失访, 患者生存率为69.63%(94/135)。预后良好组最终纳入94例,预后不良组纳入41例。2组KRAS突变类型、治疗后最佳疗效、吸烟史比较,差异有统计学意义(P<0.05)。校正混杂因素后, ADC值、D值、D*值、f值是KRAS突变NSCLC患者预后不良的影响因素(P<0.05)。ADC值、D值、D*值和f值联合预测KRAS突变NSCLC患者预后的曲线下面积(AUC)为0.933, 大于其单独预测的AUC。ADC值、D值、D*值和f值为低值患者的生存率低于高值患者, 差异有统计学意义(P<0.05)。
    结论 IVIM-DWI定量参数包括ADC值、D值、D*值和f值,是KRAS突变NSCLC患者一线同步放化疗预后的影响因素,上述参数联合预测的效能较高,可指导临床诊治,改善疾病预后。

     

    Abstract:
    Objective To explore the prognostic value of quantitative parameters of intra-voxel incoherent motion-diffusion weighted imaging (IVIM-DWI) in predicting the prognosis of patients with Kirsten rats arcomaviral oncogene homolog (KRAS) mutation non-small cell lung cancer (NSCLC) undergoing first-line concurrent chemoradiotherapy.
    Methods A total of 139 patients with KRAS-mutated NSCLC were selected as the research subjects, and all of them received first-line concurrent chemoradiotherapy. Based on follow-up results (with all-cause mortality within one year defined as the endpoint event), patients were divided into favorable prognosis group and poor prognosis group. General data and IVIM-DWI quantitative parametersapparent diffusion coefficient (ADC), diffusion coefficient (D), pseudo-diffusion coefficient (D*) and perfusion fraction (f)were compared between the two groups. Cox regression analysis was employed to identify factors influencing poor prognosis in patients with KRAS-mutated NSCLC. Receiver operating characteristic (ROC) curves were plotted to evaluate the prognostic predictive value of IVIM-DWI quantitative parameters. Kaplan-Meier (K-M) survival curves and the Log-rank test were used to analyze the relationships between IVIM-DWI quantitative parameters and prognosis in patients with KRAS-mutated NSCLC.
    Results Among the 139 patients, four were lost during follow-up, resulting in a survival rate of 69.63% (94/135). The favorable prognosis group comprised 94 patients, while the poor prognosis group included 41 patients. There were statistically significant differences in the types of KRAS mutations, the best therapeutic effect after treatment, and smoking history between the two groups (P < 0.05). After adjusting for confounding factors, ADC, D, D* and f values were identified as influencing factors for poor prognosis in patients with KRAS-mutated NSCLC (P < 0.05). The area under the curve (AUC) for the combined prediction of prognosis using ADC, D, D* and f values was 0.933, which was higher than the AUC for each parameter alone. Patients with low ADC, D, D* and f values exhibited significantly lower survival rates compared to those with high values (P < 0.05).
    Conclusion IVIM-DWI quantitative parameters, including ADC, D, D* and f values, are influencing factors for the prognosis of first-line concurrent chemoradiotherapy in patients with KRAS-mutated NSCLC. The combined predictive performance of these parameters is high, offering guidance for clinical diagnosis and treatment and potentially improving disease prognosis.

     

/

返回文章
返回